Advancements in Technology and Research to Propel Market Growth
Nearly one-third of the pre-mature traumatic deaths is caused due to hemorrhage. As a result, considerable focus and emphasis has been given to the development of effective hemorrhage treatments. Research and development activities are expected to remain the cornerstone to the overall growth of the global hemorrhage treatment market during the forecast period. As more number of patients is becoming increasingly aware of the importance of timely hemorrhage control and management, the uptake of hemorrhage treatment across various the hospitals and other clinical settings has witnessed a consistent growth. Although several conventional hemorrhage treatments are available, a number of new hemorrhage treatments have garnered immense popularity, owing to recent advancements.
One of the most prominent treatment procedures or techniques that has gained recent spotlight within the hemorrhage treatment is the aortic balloon catheter– a treatment that was first used in the 1950s. Recent piece of research related to acute trauma-induced coagulopathy has played a key role in opening up new avenues for pharmacologic agents to successfully restore homeostasis– a factor that is likely to play an imperative role in augmenting the global hemorrhage treatment market during the assessment period. The increasing emphasis on the development of pharmacological and technological therapies is likely to further strengthen the overall growth prospects of the global hemorrhage treatment.
Emergence and Utilization of Nanotechnologies to Fuel Market Growth
In recent years, advancements in technology coupled with research & development activities have played an instrumental role in the overall development of the global hemorrhage treatment market landscape. Increasing popularity and progress made by nanotechnology in recent years are projected to have a strong impact on the hemorrhage treatment. The increasing use of engineered nanomaterials, owing to various benefits, including long circulation time, improved targeting properties, and crossing biological barriers is anticipated to have a strong impact on the overall growth of the market for hemorrhage treatment during the stipulated timeframe of the study.
Nanomedicine has emerged as an ideal stroke treatment candidate in recent years, and ongoing research activities offer immense promise and potential. Some of the major advantages of leveraging nanomedicine for hemorrhage treatment include improvement in ischemic stroke, decline in neuronal death, bleeding limitation in hemorrhagic stroke, and progress in the overall prognosis-diagnosis of the stroke. Although nanomedicine has offered immense promise in the field of hemorrhage treatment, additional research and development is required. Nanomedicine and the use of nanomaterials is likely to put forward a number of solutions to the players involved in the current hemorrhage treatment market.
In addition, while nanotechnology is expected to make a noteworthy impact across the global hemorrhage treatment market landscape, recent developments in the treatment of spontaneous intracerebral hemorrhage is likely to provide boost to the overall growth of the global hemorrhage treatment market.
Research Activities in Full Swing amid COVID-19 Pandemic
The outbreak of the COVID-19 pandemic in the first quarter of 2020 has resulted in major developments across the global hemorrhage treatment market. Research and development activities have shifted gears in 2020, as researchers and scientists are increasingly focusing on discovering a link between the impact of the novel coronavirus and hemorrhage. While some evidence has emerged that a few patients suffering from the coronavirus disease are likely to develop cerebrovascular disease while hospitalized, additional research is required. Market players are expected to focus on research and consolidate the link between ischemic stroke and COVID-19. The emerging requirement to assess and evaluate the rate of bleeding and thrombotic manifestations that are majorly linked to COVID-19 coagulopathy is expected to provide considerable opportunities to the players operating in the current hemorrhage treatment market landscape.